Gastroesophageal reflux. Gastro-oesophageal reflux disease without oesophagitis
Conditions
Interventions
Intervention 1: Intervention group will receive eradication treatment including Omeprazole 20 mg BID, Clarithromycin 500 mg BID, and Amoxicillin 1000 mg BID for two weeks. Intervention 2: Control grou
Treatment - Drugs
Intervention group will receive eradication treatment including Omeprazole 20 mg BID, Clarithromycin 500 mg BID, and Amoxicillin 1000 mg BID for two weeks
Control group will receive standard treatment for reflux including Omeprazole 20 mg BID for two weeks
Sponsors
Vic-chancellor of Research and Technology, Hamadan University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The patient's with one of the following symptoms: gastro-esophageal reflux, dysphagia; heartburn; nausea; chest pain; and nuisance conditions that lead to awakening the patient will be included if they have endoscopic detection of gastritis and H. pylori infection in biopsy of gastric mucosa. The patents with following characteristics will be excluded from the study: simultaneous gastritis of fundus and antrum (pangastritis); gastric ulcer; duodenal ulcer; surgical history of esophagus, stomach, or duodenum; and history of using NSAIDs.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequency and severity of reflux. Timepoint: After four weeks. Method of measurement: History taking of heartburn, regurgitation, nausea, dysphagia, chest pain, and nocturnal. | — |
Secondary
| Measure | Time frame |
|---|---|
| Abdominal pain and diarrhea. Timepoint: Two weeks later. Method of measurement: History taking. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Jalal Poorolajal
Research Center for Health Sciences and Department of Epidemiology & Biostatistics
Outcome results
None listed